Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Sho Hiroyasu

9PUBLICATIONS

4CO-AUTHORS

Molecular targetsRadiation therapyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (9)

Sort by Publication Date:

|Dec 11, 2025

Immune checkpoint inhibitor resistance in non-small cell lung cancer: limits of vascular endothelial growth factor inhibition and new directions.

Hiroyasu Kaneda

|Oct 24, 2025

Pseudoprogression of pleural effusion in lung cancer treated with immunotherapy: a case report.

Hiroyasu Kaneda, Lan Wang, Takako Oka

|Jun 12, 2025

Potassium-competitive acid blocker has more negative impacts on clinical outcomes in patients with non-small cell lung cancer treated with checkpoint inhibitors than those of proton pump inhibitors.

Masaya Takahashi, Hitomi Nakatsukasa, Masahito Shibano

|Oct 04, 2024

Insulin-like growth factor 1 receptor expression correlates with programmed death ligand 1 expression and poor survival in non-small cell lung cancer.

Hiroaki Nagamine, Masakazu Yashiro, Megumi Mizutani

|Sep 15, 2024

Clinical impact of concomitant BIO-three use in advanced or recurrent non-small cell lung cancer treated with immune-checkpoint inhibitor.

Hitomi Nakatsukasa, Masaya Takahashi, Masahito Shibano

|Jul 03, 2021

Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non-small cell lung cancer patients with asymptomatic brain metastases.

Hiroyasu Kaneda, Kenji Sawa, Haruko Daga

Pageof 2

Frequent Collaborators

1 joint publications

Masakazu Yashiro

1 joint publications

Gregory P Stimac

1 joint publications

Susan B Hopkinson

1 joint publications

Jonathan C R Jones

Frequent Collaborators

1 joint publications

Masakazu Yashiro

1 joint publications

Gregory P Stimac

1 joint publications

Susan B Hopkinson

1 joint publications

Jonathan C R Jones

Top Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Published on : Aug 11, 2017

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on : Feb 12, 2017

Utilizing <sup>18</sup>F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing <sup>18</sup>F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on : Jul 21, 2018

See more related videos

Top Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Published on : Aug 11, 2017

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on : Feb 12, 2017

Utilizing <sup>18</sup>F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing <sup>18</sup>F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on : Jul 21, 2018

See more related videos